Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Gross Margin (2021 - 2025)

Oncology Institute (TOI) has disclosed Gross Margin for 5 consecutive years, with 165.36% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 8031.0% year-over-year to 165.36%, compared with a TTM value of 121.85% through Sep 2025, up 2754.0%, and an annual FY2024 reading of 99.67%, down 15.0% over the prior year.
  • Gross Margin was 165.36% for Q3 2025 at Oncology Institute, up from 57.36% in the prior quarter.
  • Across five years, Gross Margin topped out at 209.36% in Q4 2024 and bottomed at 17.79% in Q4 2021.
  • Average Gross Margin over 5 years is 87.7%, with a median of 85.05% recorded in 2024.
  • The sharpest move saw Gross Margin crashed -7319bps in 2022, then surged 15794bps in 2023.
  • Year by year, Gross Margin stood at 17.79% in 2021, then soared by 360bps to 46.26% in 2022, then skyrocketed by 341bps to 204.2% in 2023, then grew by 3bps to 209.36% in 2024, then decreased by -21bps to 165.36% in 2025.
  • Business Quant data shows Gross Margin for TOI at 165.36% in Q3 2025, 57.36% in Q2 2025, and 54.91% in Q1 2025.